BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Industry & Community
Shilpa CDMO's $50 Million Expansion: What India's Latest Peptide Manufacturing Investment Means for UK Research Supply Chains
Shilpa CDMO announced a $50 million phased investment in solid-phase peptide synthesis capacity at its Raichur, India campus on 3 November 2026, with its first commercial manufacturing line due to open in December. The move reinforces India's emergence as a significant alternative to European and Chinese sources for peptide APIs, with implications for procurement diversification strategies at UK research organisations.
08 Nov 2026
Industry & Community
Samsung Biologics Clears the Tender Threshold: What PolyPeptide's Imminent Delisting Means for Peptide API Supply
The additional acceptance period for Samsung Biologics' CHF 1.46 billion bid for Swiss peptide CDMO PolyPeptide Group closed on 30 October, with the main period already confirming an 87.59–87.92% tender rate. Completion is targeted by end of November, pending multi-jurisdiction regulatory clearances. Research procurement teams should now plan for the operational consequences of this ownership change on one of the sector's largest GLP-1 peptide API suppliers.
31 Oct 2026
Industry & Community
No Road Back for Large-Scale GLP-1 Compounding: What the Closing 503B Pathway and Chinese API Scandal Mean for Research Procurement
The FDA's proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list — combined with FOIA-obtained inspection reports documenting contamination and falsified records at two Chinese API suppliers — signals that the legal and supply-chain foundations of large-scale GLP-1 compounding have effectively collapsed. UK research procurement teams that source these peptides should understand what remains lawful, what does not, and where the supply risks…
27 Oct 2026
Industry & Community
Samsung Biologics Clears the PolyPeptide Threshold: What the Tender Offer Result Means for Peptide API Supply Chains
Samsung Biologics has secured 87.88% of PolyPeptide Group shares — well above the two-thirds minimum — and opened a second acceptance period through 30 October, with the CHF 1.46 billion acquisition on track to close by end-November. For research procurement teams, the deal reshapes who controls a significant share of global peptide API capacity.
18 Oct 2026
Industry & Community
REX Peptide ETF Launches on Nasdaq: What the First Dedicated Peptide Equity Vehicle Signals About Sector Capital and Research-Supply Dynamics
REX Shares launched the REX Peptide ETF (PEPT) on Nasdaq on 14 October 2026, offering the first single-ticker vehicle tracking the full peptide value chain from drug developers to CDMOs. The launch provides research-procurement professionals with a useful map of where institutional capital sees durable demand — and which parts of the supply chain are considered investable.
14 Oct 2026
Industry & Community
Multiplexed LC-HRMS for Nine GLP-1 Receptor Agonists: What a New Validated Method Means for Peptide Quality Control in Research Labs
A validated multiplexed LC-HRMS method covering nine structurally diverse GLP-1 receptor agonists — including survodutide, tirzepatide, and three investigational Phase III compounds — has been published in the Journal of Chromatography A. For research-procurement teams, it signals a meaningful step forward in the analytical toolkit available for identity confirmation and purity profiling of peptide reference materials.
13 Oct 2026
Industry & Community
Samsung Biologics / PolyPeptide: What the Tender Close on 12 October Means for Peptide API Supply Chains
The main acceptance window for Samsung Biologics' CHF 1.46 billion all-cash offer for Swiss peptide CDMO PolyPeptide Group closes at 4 p.m. Swiss time on 12 October 2026. With a 40% premium, unanimous board support, and the majority shareholder committed to tender, the transaction is broadly expected to clear — reshaping the ownership of one of Europe's largest peptide API manufacturing networks at a moment of acute GLP-1 supply-chain pressure.
04 Oct 2026
Industry & Community
Same Day, Different Strategies: How Lilly's $6.5 Billion Houston Groundbreaking and Novo's Capital Markets Day Reveal Diverging Paths in the Oral GLP-1 Manufacturing Race
On 21 September 2026, Eli Lilly broke ground on a $6.5 billion API facility in Houston and Novo Nordisk hosted its Capital Markets Day in London, where it pledged to scale oral GLP-1 manufacturing tenfold by 2030. The two announcements — made on the same day — illuminate fundamentally different production strategies and have direct implications for the peptide supply chain.
26 Sep 2026
Industry & Community
The Oral Peptide Delivery Race: Approvals, Formulation Science, and the Investment Wave Reshaping Drug Development in 2026
A cluster of FDA approvals, landmark partnership deals, and oversubscribed financing rounds in 2026 signals that oral delivery of peptide therapeutics is transitioning from a persistent scientific aspiration to a commercially credible drug class. Research-procurement teams sourcing peptide APIs and formulation materials need to understand the technical and market forces now driving this shift.
21 Sep 2026
Industry & Community
Samsung Biologics' PolyPeptide Tender Window Opens Today: What the CHF 1.46 Billion Bid Means for Peptide API Supply
The formal acceptance period for Samsung Biologics' all-cash offer to acquire PolyPeptide Group opened on 15 September 2026, running until 12 October. With PolyPeptide's largest shareholder already committed to tender its 55.65% stake, completion appears probable — reshaping who controls a significant share of globally validated solid-phase peptide synthesis capacity.
15 Sep 2026
Industry & Community
Peptide CDMO Consolidation Accelerates: Samsung Biologics Launches Formal Tender for PolyPeptide as CordenPharma Closes AmbioPharm Deal
Samsung Biologics published its formal tender offer prospectus for Swiss peptide CDMO PolyPeptide Group on 31 August 2026, opening a ten-day cooling-off period ahead of the main acceptance window. The CHF 1.46 billion all-cash bid — carrying a 40 per cent premium to the pre-speculation share price — arrives weeks after CordenPharma completed its acquisition of AmbioPharm, signalling a sharp acceleration in consolidation among specialist peptide contract manufacturers.
02 Sep 2026
Industry & Community
Samsung Biologics' $1.8 Billion PolyPeptide Acquisition: What Peptide CDMO Consolidation Means for Research Supply Chains
Samsung Biologics has launched an all-cash tender offer to acquire Swiss peptide CDMO PolyPeptide Group for approximately $1.8 billion — the largest biopharma acquisition in South Korean history. With the formal offer prospectus due by 31 August 2026, procurement teams should understand what accelerating CDMO consolidation means for peptide API availability and supply-chain resilience.
11 Aug 2026